Going with the flow, and beyond, in myeloma.
Barlogie
Bart
B
University of Arkansas for Medical Sciences, USA.
Epstein
Joshua
J
Shaughnessy
John D
JD
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001761:Bleomycin / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D018365:Neoplasm, Residual; D011237:Predictive Value of Tests; D033581:Stem Cell Transplantation / Q000379:methods; D015996:Survival Rate; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D016685:Mitomycin; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D002945:Cisplatin; D002330:Carmustine